Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | AGXT | P21549 | 2/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.48 |
| ▸ | TUBB | P07437 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL2382371 | 0.95 | IDO1 (0.56) | IDO1CA12CA1CA2CA7 | |
| Hydrochloric Acid SCHEMBL29127872 | 0.78 | CALM1 (0.60) | IDO1TAAR1MAOBALOX15TUBB4A | |
| SCHEMBL5326580 | 0.77 | IDO1 (0.58) | IDO1CA12CA1CA2CA7 | |
| Hydrochloric Acid SCHEMBL2820652 | 0.76 | NQO1 (0.64) | CA12CA1CA2CA7CA9 | |
| Iodide SCHEMBL7544118 | 0.76 | TAAR1 (0.59) | IDO1CA12CA1CA2CA7 | |
| SCHEMBL27884 | 0.76 | LTA4H (0.81) | IDO1CA12CA1CA2CA7 | |
| SCHEMBL25986524 | 0.76 | LTA4H (0.81) | IDO1CA12CA1CA2CA7 | |
| SCHEMBL834551 | 0.76 | TAAR1 (0.73) | IDO1CA12CA1CA2CA7 | |
| SCHEMBL1425001 | 0.76 | LTA4H (0.81) | IDO1CA12CA1CA2CA7 | |
| Hydrochloric Acid SCHEMBL5324187 | 0.75 | ALDH1A1 (0.55) | ALDH1A1TSHRCALM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025242747-A1 | MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS | MERCK PATENT GMBH (DE) | 2025-11-27 | — | — | WO | claimed |
| WO-2025242747-A1 | MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS | MERCK PATENT GMBH (DE) | 2025-11-27 | — | — | WO | disclosed |
| US-20250296935-A1 | Diamine Derivatives as Inhibitors of Leukotriene A4 Hydrolase | CELLTAXIS LLC (US) | 2025-09-25 | — | — | US | disclosed |
| US-12173009-B2 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | CELLTAXIS, LLC (US) | 2024-12-24 | — | — | US | disclosed |
| US-20240002344-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | FIBROGEN, INC. | 2024-01-04 | — | — | US | disclosed |
| US-20230250104-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELLTAXIS LLC (US) | 2023-08-10 | — | — | US | disclosed |
| EP-4204400-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | Fibrogen, Inc. (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-116348450-A | Compounds, compositions and methods for histone lysine demethylase inhibition | 菲布罗根有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-109153646-B | Pyridine dicarboxamide derivatives as bromodomain inhibitors | 葛兰素史克知识产权第二有限公司 | 2022-08-02 | — | — | CN | disclosed |
| US-11275265-B2 | Control of illumination spectra for LCD displays | MOLECULED LTD. (IL) | 2022-03-15 | — | — | US | disclosed |
| US-20060287341-A1 | Triazolopyrimidine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2006-12-21 | — | — | US | disclosed |
| US-7119206-B2 | Derivative of dihydro-dibenzo (a) anthracenes and their use as selective estrogen receptor modulators | ELI LILLY AND COMPANY (US) | 2006-10-10 | — | — | US | disclosed |
| US-20060122386-A1 | Derivative of dihydro-dibenzo (a) anthracenes and their use as selective estrogen receptor modulators | ELI LILLY AND COMPANY | 2006-06-08 | — | — | US | disclosed |
| WO-2006060109-A1 | 2-AMINOPYRIDINE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2006-06-08 | — | — | WO | disclosed |
| EP-1656368-A2 | SUBSTITUTED HERTOCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | Bristol-Myers Squibb Company (US) | 2006-05-17 | — | — | EP | disclosed |
| CN-1684958-A | Dihydro-dibenzo (A) anthracenes and relative compounds,composition and method | LILLY CO ELI (US) | 2005-10-19 | — | — | CN | disclosed |
| EP-1546139-A1 | DERIVATIVE OF DIHYDRO-DIBENZO (A) ANTHRACENES AND THEIR USE AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004029047-A1 | DERIVATIVE OF DIHYDRO-DIBENZO (A) ANTHRACENES AND THEIR USE AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-04-08 | — | — | WO | disclosed |
| US-20040063700-A1 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
| WO-2004004665-A2 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287341-A1 | Triazolopyrimidine cannabinoid receptor 1 antagonists | CNR1, CNR2, GPR68 | IDO1 1282/4885CA12 4523/4885CA1 3284/4885 |
| US-20060122386-A1 | Derivative of dihydro-dibenzo (a) anthracenes and their use as selective estrogen receptor modulators | ESR1, GPER1, ESR2 | IDO1 2867/4885CA12 2088/4885CA1 928/4885 |
| US-12173009-B2 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | IDO1 941/4885CA12 3751/4885CA1 1259/4885 |
| US-20250296935-A1 | Diamine Derivatives as Inhibitors of Leukotriene A4 Hydrolase | LTA4H, LTB4R, LTC4S | IDO1 941/4885CA12 3751/4885CA1 1259/4885 |
| US-20230250104-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTB4R, LTC4S | IDO1 941/4885CA12 3751/4885CA1 1259/4885 |
| US-20240002344-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | KDM5C, KDM5B, KDM5A | IDO1 1504/4885CA12 3916/4885CA1 3189/4885 |
| US-20040063700-A1 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | GPR119, SLC5A2, GLP1R | IDO1 2525/4885CA12 2448/4885CA1 3042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.